search
Back to results

The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence

Primary Purpose

Alcohol Use Disorder (AUD)

Status
Recruiting
Phase
Phase 2
Locations
Australia
Study Type
Interventional
Intervention
Cannabidiol (CBD)
Placebo
Sponsored by
South West Sydney Local Health District
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcohol Use Disorder (AUD) focused on measuring Alcohol Withdrawal, Alcohol-Related Disorders, Substance-Related Disorders, Mental Disorders

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female patients between ages of 18 and 65 meeting DSM-5 criteria for current alcohol use disorder
  • Adequate cognition and English language skills to give valid consent and complete research interviews;
  • A BrAC reading of 0.00
  • Must have a stable residence and be able to identify an individual who could locate subject if needed
  • Provision of informed consent

Exclusion Criteria:

  • Active major psychological disorder associated with psychosis, significant suicide risk
  • Pregnancy or lactation - women shall be advised to use reliable contraception for the duration of drug therapy and a urine pregnancy test will be performed where necessary;
  • Dependence on any substance other than nicotine (eg methadone)
  • Diagnosis of epilepsy, and/or current use of anti-epileptic drugs (AED)
  • Liver failure with jaundice or prolonged INR above 1.3
  • Medical complications such as liver failure, cardiac ischemia or conduction abnormalities, renal impairment or unstable elevated vital signs (systolic blood pressure > 180, diastolic blood pressure > 120 or heart rate > 150)
  • Severe cognitive impairment or insufficient English or literacy to complete study processes
  • Concurrent use of drugs potentially exacerbated by CBD via CYP3A5 including cardiac medication (e.g. betablockers, calcium channel blockers and statins), macrolides and recent antihistamine use.
  • Claustrophobia;
  • Extreme obesity;
  • Previous brain surgery;
  • Ever employed as a machinist, a welder or a metal worker;
  • Metal items such as pacemakers; aneurysm clips in the brain; metal dental implants; metallic fragments in the eye or anywhere else; insulin pump; metal implants; hearing aid or a prosthetic device.

Sites / Locations

  • Drug Health Services, Royal Prince Alfred HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Cannabidiol (CBD)

Placebo

Arm Description

For a total of three days, so that both study participants and staff are blind to treatment condition

For a total of three days, so that both study participants and staff are blind to treatment condition

Outcomes

Primary Outcome Measures

Changes in High Frequency Heart Rate Variability
To assess whether acute ingestion of CBD can modulate heart rate variability when responding to alcohol cues compared to neutral cues
Changes in Skin Conductance Levels
To assess whether acute ingestion of CBD modulates skin conductance levels when responding to alcohol cues compared to neutral cues
Changes in Brain Activation
To assess whether acute ingestion of CBD can attenuate brain activation via blood oxygen level dependent (BOLD) in areas associated with alcohol cue-elicited craving measured by an fMRI machine
Changes in Neurotransmitter levels in the Brain
To assess whether CBD treatment leads to changes in brain levels of the neurotransmitters: glutamate, gamma-aminobutyric acid (GABA), N-acetylaspartate (NAA) and glutathione (GSH)
Heavy Drinking Days
Reduction in Heavy Drinking Days (HDD; defined as 4 or more drinks in a day for women and five or more drinks in a day for men). This will be measured by the Timeline Follow Back.
Absence of any Heavy Drinking Day
Measured by Timeline Follow Back
Mean Alcohol Consumption per Drinking Day
Measured by Timeline Follow Back
Alcohol Dependence Severity
Measured by the Alcohol Dependence Scale. The minimum score is 0 and the maximum score is 47. A higher score indicates more severe dependence.
Alcohol Craving
As measured by the Penn Alcohol Craving Scale (PACS), which measures the amount of time spent thinking and craving for alcohol, difficulty in resisting consumption of alcohol if present and hypothetical pleasure associated with consumption of alcohol. This scale has a minimum score of 0 and a maximum score of 6. A higher score indicates greater levels of craving.

Secondary Outcome Measures

Changes in Alcohol Craving
To assess whether acute ingestion of CBD can modulate subjective measures of alcohol cue elicited craving. This will be measured during the fMRI scan using the Visual Analogue Scale. This scale will assess alcohol craving, thirst and anxiety.
Changes in Alcohol Craving in response to alcohol cues
To assess whether acute ingestion of CBD can modulate subjective measures of alcohol cue elicited craving. This will be measured before and after the fMRI scan using the Alcohol Urge Questionnaire (AUQ). This Questionnaire consists of 8 questions that are scored on a Likert scale of 7 points. Two of the questions are reversed scored. Total score is computed by averaging the item scores. A greater score indicates greater craving.
Changes in Positive and Negative Mood States
To assess whether acute ingestion of CBD can modulate subjective measures of positive and negative mood states following alcohol cues. This will be measured before and after the fMRI scan using the Positive and Negative Affect Schedule (PANAS).
Changes in Anxiety
Measured by cumulative scores on the DASS-21 Anxiety Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more anxiety.
Changes in Depression
Measured by cumulative scores on the DASS-21 Depression Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates greater depression.
Changes in Stress
Measured by cumulative scores on the DASS-21 Stress Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more stress.
Sleep Disturbances
As measured by the ISI (Insomnia Severity Index). This Index has a minimum score of 0 and a maximum score of 28. The higher the score indicates more severe insomnia.
Sleep Disturbances
To assess whether acute ingestion of CBD has any impact of sleep. This will be measured by an Actiwatch. The Actiwatch records motion and light to determine information about participants sleep and wake patterns. The participants will wear this watch for 48 hours on two separate occasions.
Changes in Tension Reduction Alcohol Expectancies
To assess whether CBD treatment can reduce participants need to use alcohol to attenuate tension states (such as anxiety) as measured by the Tension Reduction subscale of the Alcohol Expectancy Questionnaire. Higher scores indicate greater reliance on alcohol to reduce tension/ anxiety.
Lifetime Consequences related to Drinking
To examine the adverse consequences a participant has experienced in their lifetime due to alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. This is measured using the Drinker Inventory of Consequences Lifetime Edition (DrInC-2L). Higher scores indicate more consequences.
Recent Consequences related to Drinking
To examine the adverse consequences a participant has experienced in the last 3 months due to alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. This is measured using the Drinker Inventory of Consequences Recent Edition (DrInC-2R). Higher scores indicate more consequences.
Behavioural Inhibition/Avoidance Scales
The BIS/BAS Scale is a 20-item self-report questionnaire designed to measure two motivational systems: the behavioral inhibition system (BIS), which corresponds to motivation to avoid aversive outcomes, and the behavioral activation system (BAS), which corresponds to motivation to approach goal-oriented outcomes.
Obsessive Compulsive Drinking
To assess an individuals obsessive thoughts about alcohol use and compulsive behaviours towards drinking as measured by the Obsessive Compulsive Drinking Scale. Six of the questions measure to obsession and eight of the questions measure compulsivity. Higher scores on these subscales indicate more obsession and compulsion, respectively.
Self-Confidence to Remain Abstinent
To measure an individual's self-confidence in avoiding alcohol through the Alcohol Abstinence Self-Efficacy Scale (AASE). There are 20 questions and each is scored from 0 to 4. Higher scores on this scale indicate more self-confidence.
Intolerance of Uncertainty
To assess an individual's reactions to situations that are ambiguous, the consequences of being uncertain, and attempts the individual might make to control the future. This will be measured through the Intolerance of Uncertainty Scale (IUS). This scale includes 27-items that are scored on a Likert scale (1 - Not at all characteristic of me to 5 - entirely characteristic of me). All scores are summed up and a higher score indicates greater inability to deal with uncertainty.
Impulsivity
To assess an individual's impulsivity across four domains: urgency, lack of premeditation and perseverance, and sensation seeking. This will be measured through the Impulsivity Scale (UPPS). Greater scores on this scale indicate greater impulsivity.
Alcohol Withdrawal
To assess an individual's severity of alcohol withdrawal through the Clinical Institute Withdrawal Assessment of Alcohol Scale - Revised (CIWA-Ar). Greater scores on this scale indicate the participant is experiencing greater alcohol withdrawal symptoms.
Approach and Avoidance towards Alcohol
To assess an individual's automatic action tendencies (either approve or avoid) towards alcohol. This will be measured through the Approach Avoidance Task (AAT).
Response Time and Visuospatial Skills
To assess an individual's response time and visuospatial skills through the Trail Making Test Part A (TMT-A).
Set-shifting Flexibility, Attention, and Inhibition
To assess an individual's set-shifting flexibility, attention and inhibition through the Trail Making Test Part B (TMT-B).
Risk/Reward Taking Behaviour
To assess an individual's risk taking behaviour measured through the Balloon Analogue Risk Task (BART).
Decision Making
To assess an individual's decision making skills measured through the Columbia Card Task (CCT).
Response Inhibition
To assess an individual's ability to inhibit prepotent responses measured through the Stroop task.
Working Memory Capacity to Update Information
To assess an individual's capacity to update working memory information measured through the N-back task.
Working Memory Capacity to Shift Information
To assess an individual's capacity to shift between two tasks measured by the Number Letter task.
Markers of neuroinflammation
As measured by differences in blood sampling levels of glutathione.
Markers of Stress
As measured by differences in blood sampling levels of cortisol. This will be measured at rest, before the fMRI scan and following the fMRI scan.

Full Information

First Posted
May 15, 2022
Last Updated
May 31, 2022
Sponsor
South West Sydney Local Health District
Collaborators
University of Sydney, Lambert Initiative for Cannabinoid Therapeutics
search

1. Study Identification

Unique Protocol Identification Number
NCT05387148
Brief Title
The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence
Official Title
The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence: An Exploratory Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 2022 (Anticipated)
Primary Completion Date
June 2023 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
South West Sydney Local Health District
Collaborators
University of Sydney, Lambert Initiative for Cannabinoid Therapeutics

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study will explore the psychophysiological and neurobiological and mechanisms of CBD in participants with alcohol use disorder
Detailed Description
New treatment strategies for treating symptoms of alcohol dependence are urgently needed. Although alcohol related disorders are a leading cause of preventable death in Australia, their treatment is generally not evidence based. Cannabidiol (CBD) may serve as a novel pharmacotherapeutic due to its anxiolytic, anti-epileptic, neuro-protective, antioxidant and neuroprotective properties as well as a particularly safe side effect profile. Further, CBD has been shown to modulate drug craving and seeking behaviours. This project will examine whether CBD exerts an effect on cue-induced craving by reducing activation in areas of the brain responsive to alcohol cues in comparison to a placebo. This study will use functional magnetic resonance imaging (fMRI) to examine activity in the brain while participants are exposed alcohol related cues and magnetic resonance spectroscopy (MRS) to determine levels of neurotransmitters that may be responsible for craving. In addition, we aim to investigate the effects of CBD on autonomic nervous system parameters associated with alcohol withdrawal symptoms and anxiety, such as heart rate variability and skin conductance. Additionally, clinical outcome measures will be taken to investigate CBDs influence on drinking, sleep This project uses a randomised, double blind, crossover design with 800mg CBD vs matched placebo. The dosing paradigm will consist of one dose per day for three days per arm with a 18 days washout period in-between arms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Use Disorder (AUD)
Keywords
Alcohol Withdrawal, Alcohol-Related Disorders, Substance-Related Disorders, Mental Disorders

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Masking Description
Double-blind
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cannabidiol (CBD)
Arm Type
Experimental
Arm Description
For a total of three days, so that both study participants and staff are blind to treatment condition
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
For a total of three days, so that both study participants and staff are blind to treatment condition
Intervention Type
Drug
Intervention Name(s)
Cannabidiol (CBD)
Intervention Description
Four 200mg soft gel capsules of Cannabidiol (CBD) will be taken orally daily for a total of 3 days.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
The placebo will be identical in appearance, taste, and composition except for the active ingredient of pure CBD. So, four 200mg soft gel capsules of the placebo will be taken orally daily for a total of 3 days.
Primary Outcome Measure Information:
Title
Changes in High Frequency Heart Rate Variability
Description
To assess whether acute ingestion of CBD can modulate heart rate variability when responding to alcohol cues compared to neutral cues
Time Frame
22 days
Title
Changes in Skin Conductance Levels
Description
To assess whether acute ingestion of CBD modulates skin conductance levels when responding to alcohol cues compared to neutral cues
Time Frame
22 days
Title
Changes in Brain Activation
Description
To assess whether acute ingestion of CBD can attenuate brain activation via blood oxygen level dependent (BOLD) in areas associated with alcohol cue-elicited craving measured by an fMRI machine
Time Frame
22 days
Title
Changes in Neurotransmitter levels in the Brain
Description
To assess whether CBD treatment leads to changes in brain levels of the neurotransmitters: glutamate, gamma-aminobutyric acid (GABA), N-acetylaspartate (NAA) and glutathione (GSH)
Time Frame
22 days
Title
Heavy Drinking Days
Description
Reduction in Heavy Drinking Days (HDD; defined as 4 or more drinks in a day for women and five or more drinks in a day for men). This will be measured by the Timeline Follow Back.
Time Frame
Up to 43 days
Title
Absence of any Heavy Drinking Day
Description
Measured by Timeline Follow Back
Time Frame
Up to 43 days
Title
Mean Alcohol Consumption per Drinking Day
Description
Measured by Timeline Follow Back
Time Frame
Up to 43 days
Title
Alcohol Dependence Severity
Description
Measured by the Alcohol Dependence Scale. The minimum score is 0 and the maximum score is 47. A higher score indicates more severe dependence.
Time Frame
Baseline
Title
Alcohol Craving
Description
As measured by the Penn Alcohol Craving Scale (PACS), which measures the amount of time spent thinking and craving for alcohol, difficulty in resisting consumption of alcohol if present and hypothetical pleasure associated with consumption of alcohol. This scale has a minimum score of 0 and a maximum score of 6. A higher score indicates greater levels of craving.
Time Frame
Up to 43 days
Secondary Outcome Measure Information:
Title
Changes in Alcohol Craving
Description
To assess whether acute ingestion of CBD can modulate subjective measures of alcohol cue elicited craving. This will be measured during the fMRI scan using the Visual Analogue Scale. This scale will assess alcohol craving, thirst and anxiety.
Time Frame
22 days
Title
Changes in Alcohol Craving in response to alcohol cues
Description
To assess whether acute ingestion of CBD can modulate subjective measures of alcohol cue elicited craving. This will be measured before and after the fMRI scan using the Alcohol Urge Questionnaire (AUQ). This Questionnaire consists of 8 questions that are scored on a Likert scale of 7 points. Two of the questions are reversed scored. Total score is computed by averaging the item scores. A greater score indicates greater craving.
Time Frame
22 days
Title
Changes in Positive and Negative Mood States
Description
To assess whether acute ingestion of CBD can modulate subjective measures of positive and negative mood states following alcohol cues. This will be measured before and after the fMRI scan using the Positive and Negative Affect Schedule (PANAS).
Time Frame
22 days
Title
Changes in Anxiety
Description
Measured by cumulative scores on the DASS-21 Anxiety Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more anxiety.
Time Frame
Up to 43 days
Title
Changes in Depression
Description
Measured by cumulative scores on the DASS-21 Depression Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates greater depression.
Time Frame
Up to 43 days
Title
Changes in Stress
Description
Measured by cumulative scores on the DASS-21 Stress Scale. This scale has a minimum score of 0 and maximum score of 21. A higher score indicates more stress.
Time Frame
Up to 43 days
Title
Sleep Disturbances
Description
As measured by the ISI (Insomnia Severity Index). This Index has a minimum score of 0 and a maximum score of 28. The higher the score indicates more severe insomnia.
Time Frame
Up to 43 days
Title
Sleep Disturbances
Description
To assess whether acute ingestion of CBD has any impact of sleep. This will be measured by an Actiwatch. The Actiwatch records motion and light to determine information about participants sleep and wake patterns. The participants will wear this watch for 48 hours on two separate occasions.
Time Frame
22 days
Title
Changes in Tension Reduction Alcohol Expectancies
Description
To assess whether CBD treatment can reduce participants need to use alcohol to attenuate tension states (such as anxiety) as measured by the Tension Reduction subscale of the Alcohol Expectancy Questionnaire. Higher scores indicate greater reliance on alcohol to reduce tension/ anxiety.
Time Frame
Up to 43 days
Title
Lifetime Consequences related to Drinking
Description
To examine the adverse consequences a participant has experienced in their lifetime due to alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. This is measured using the Drinker Inventory of Consequences Lifetime Edition (DrInC-2L). Higher scores indicate more consequences.
Time Frame
Baseline
Title
Recent Consequences related to Drinking
Description
To examine the adverse consequences a participant has experienced in the last 3 months due to alcohol abuse in five areas: Interpersonal, Physical, Social, Impulsive, and Intrapersonal. This is measured using the Drinker Inventory of Consequences Recent Edition (DrInC-2R). Higher scores indicate more consequences.
Time Frame
Baseline
Title
Behavioural Inhibition/Avoidance Scales
Description
The BIS/BAS Scale is a 20-item self-report questionnaire designed to measure two motivational systems: the behavioral inhibition system (BIS), which corresponds to motivation to avoid aversive outcomes, and the behavioral activation system (BAS), which corresponds to motivation to approach goal-oriented outcomes.
Time Frame
22 days
Title
Obsessive Compulsive Drinking
Description
To assess an individuals obsessive thoughts about alcohol use and compulsive behaviours towards drinking as measured by the Obsessive Compulsive Drinking Scale. Six of the questions measure to obsession and eight of the questions measure compulsivity. Higher scores on these subscales indicate more obsession and compulsion, respectively.
Time Frame
22 days
Title
Self-Confidence to Remain Abstinent
Description
To measure an individual's self-confidence in avoiding alcohol through the Alcohol Abstinence Self-Efficacy Scale (AASE). There are 20 questions and each is scored from 0 to 4. Higher scores on this scale indicate more self-confidence.
Time Frame
22 days
Title
Intolerance of Uncertainty
Description
To assess an individual's reactions to situations that are ambiguous, the consequences of being uncertain, and attempts the individual might make to control the future. This will be measured through the Intolerance of Uncertainty Scale (IUS). This scale includes 27-items that are scored on a Likert scale (1 - Not at all characteristic of me to 5 - entirely characteristic of me). All scores are summed up and a higher score indicates greater inability to deal with uncertainty.
Time Frame
22 days
Title
Impulsivity
Description
To assess an individual's impulsivity across four domains: urgency, lack of premeditation and perseverance, and sensation seeking. This will be measured through the Impulsivity Scale (UPPS). Greater scores on this scale indicate greater impulsivity.
Time Frame
22 days
Title
Alcohol Withdrawal
Description
To assess an individual's severity of alcohol withdrawal through the Clinical Institute Withdrawal Assessment of Alcohol Scale - Revised (CIWA-Ar). Greater scores on this scale indicate the participant is experiencing greater alcohol withdrawal symptoms.
Time Frame
22 days
Title
Approach and Avoidance towards Alcohol
Description
To assess an individual's automatic action tendencies (either approve or avoid) towards alcohol. This will be measured through the Approach Avoidance Task (AAT).
Time Frame
Up to 43 days
Title
Response Time and Visuospatial Skills
Description
To assess an individual's response time and visuospatial skills through the Trail Making Test Part A (TMT-A).
Time Frame
Up to 43 days
Title
Set-shifting Flexibility, Attention, and Inhibition
Description
To assess an individual's set-shifting flexibility, attention and inhibition through the Trail Making Test Part B (TMT-B).
Time Frame
Up to 43 days
Title
Risk/Reward Taking Behaviour
Description
To assess an individual's risk taking behaviour measured through the Balloon Analogue Risk Task (BART).
Time Frame
Up to 43 days
Title
Decision Making
Description
To assess an individual's decision making skills measured through the Columbia Card Task (CCT).
Time Frame
Up to 43 days
Title
Response Inhibition
Description
To assess an individual's ability to inhibit prepotent responses measured through the Stroop task.
Time Frame
Up to 43 days
Title
Working Memory Capacity to Update Information
Description
To assess an individual's capacity to update working memory information measured through the N-back task.
Time Frame
Up to 43 days
Title
Working Memory Capacity to Shift Information
Description
To assess an individual's capacity to shift between two tasks measured by the Number Letter task.
Time Frame
Up to 43 days
Title
Markers of neuroinflammation
Description
As measured by differences in blood sampling levels of glutathione.
Time Frame
Up to 43 days
Title
Markers of Stress
Description
As measured by differences in blood sampling levels of cortisol. This will be measured at rest, before the fMRI scan and following the fMRI scan.
Time Frame
Up to 43 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female patients between ages of 18 and 65 meeting DSM-5 criteria for current alcohol use disorder Adequate cognition and English language skills to give valid consent and complete research interviews; A BrAC reading of 0.00 Must have a stable residence and be able to identify an individual who could locate subject if needed Provision of informed consent Exclusion Criteria: Active major psychological disorder associated with psychosis, significant suicide risk Pregnancy or lactation - women shall be advised to use reliable contraception for the duration of drug therapy and a urine pregnancy test will be performed where necessary; Dependence on any substance other than nicotine (eg methadone) Diagnosis of epilepsy, and/or current use of anti-epileptic drugs (AED) Liver failure with jaundice or prolonged INR above 1.3 Medical complications such as liver failure, cardiac ischemia or conduction abnormalities, renal impairment or unstable elevated vital signs (systolic blood pressure > 180, diastolic blood pressure > 120 or heart rate > 150) Severe cognitive impairment or insufficient English or literacy to complete study processes Concurrent use of drugs potentially exacerbated by CBD via CYP3A5 including cardiac medication (e.g. betablockers, calcium channel blockers and statins), macrolides and recent antihistamine use. Claustrophobia; Extreme obesity; Previous brain surgery; Ever employed as a machinist, a welder or a metal worker; Metal items such as pacemakers; aneurysm clips in the brain; metal dental implants; metallic fragments in the eye or anywhere else; insulin pump; metal implants; hearing aid or a prosthetic device.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kirsten Morley, PhD
Phone
+61295153636
Email
kirsten.morley@sydney.edu.au
Facility Information:
Facility Name
Drug Health Services, Royal Prince Alfred Hospital
City
Sydney
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kirsten Morley, PhD
Email
Kirsten.morley@sydney.edu.au
First Name & Middle Initial & Last Name & Degree
Central Contact Line
Phone
0459877108
Email
sydneyalcoholtreatmentgroup@gmail.com
First Name & Middle Initial & Last Name & Degree
Paul Haber, MBBS
First Name & Middle Initial & Last Name & Degree
Warren Logge, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

The Efficacy and Neurobehavioural Mechanism of Cannabidiol (CBD) for Alcohol Dependence

We'll reach out to this number within 24 hrs